Extrarenal Extracranial Rhabdoid Tumor

• Extrarenal Extracranial Rhabdoid Tumor (EERT) is a very rare, aggressive cancer primarily affecting young children.
• It originates outside the kidneys and brain, often presenting in soft tissues or various organs.
• Diagnosis is challenging due to varied symptoms and requires a biopsy for confirmation, often revealing a SMARCB1 gene mutation.
• Treatment typically involves aggressive multimodal approaches, including surgery, chemotherapy, and radiation therapy.
• The prognosis for EERT is generally poor, highlighting the need for early diagnosis and ongoing research into new therapies.

What is Extrarenal Extracranial Rhabdoid Tumor?

Extrarenal Extracranial Rhabdoid Tumor (EERT) is a highly malignant and rare neoplasm characterized by its aggressive nature and tendency to affect very young patients, often under the age of three. The term “extrarenal” signifies that the tumor does not originate in the kidneys, distinguishing it from the more commonly known renal rhabdoid tumor. Similarly, “extracranial” indicates that it arises outside the brain and spinal cord, typically in soft tissues, liver, lung, or other visceral organs.

EERTs are genetically defined by inactivating mutations in the SMARCB1 gene, a tumor suppressor gene located on chromosome 22. This genetic alteration is crucial for diagnosis and understanding the tumor’s biology, as it leads to uncontrolled cell proliferation and resistance to conventional therapies. The rarity of EERT, with an incidence of less than one case per million children, contributes to the limited understanding of its exact prevalence and optimal treatment strategies.

Symptoms and Diagnosis of Extrarenal Extracranial Rhabdoid Tumor

The presentation of extrarenal extracranial rhabdoid tumor symptoms can be highly variable and non-specific, depending on the tumor’s primary location. This often leads to delayed diagnosis, as initial symptoms may mimic more common pediatric conditions. Common signs can include a palpable mass, pain, swelling, or functional impairment of the affected organ. For instance, a tumor in the abdomen might present as an enlarging belly, while one in the chest could cause respiratory distress.

Diagnosing EERT typically involves a combination of imaging studies and tissue biopsy. Imaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT) scans, and positron emission tomography (PET) scans are used to locate the tumor, assess its size, and check for metastasis. However, definitive diagnosis relies on histological examination of a biopsy specimen, which reveals characteristic rhabdoid cells. Immunohistochemical staining for SMARCB1 protein loss is a critical diagnostic marker, often followed by genetic testing to confirm the underlying SMARCB1 mutation.

• Common Symptom Indicators:
  • Presence of a rapidly growing mass or swelling
  • Unexplained pain or discomfort
  • Changes in appetite or weight loss
  • Respiratory difficulties (if lung or chest wall affected)
  • Neurological signs (if near nerves or spinal cord)

Treatment and Prognosis for Extrarenal Extracranial Rhabdoid Tumor

Due to the aggressive nature of this cancer, extrarenal extracranial rhabdoid tumor treatment is typically intensive and multimodal. The primary goal is to achieve complete tumor resection, which is often challenging given the tumor’s infiltrative growth and common presentation in critical anatomical locations. Surgical removal, when feasible, is usually followed by systemic chemotherapy, which may involve high-dose regimens to combat the tumor’s rapid growth and metastatic potential. Radiation therapy is also frequently employed, either as a primary treatment or to target residual disease or metastatic sites.

The extrarenal extracranial rhabdoid tumor prognosis remains challenging, with generally poor outcomes, particularly in cases of metastatic disease or incomplete surgical resection. Survival rates are significantly lower compared to many other pediatric cancers, underscoring the urgent need for more effective therapies. Ongoing research focuses on identifying novel therapeutic targets, including drugs that can restore SMARCB1 function or exploit other vulnerabilities in rhabdoid tumor cells. Clinical trials exploring new chemotherapy agents, targeted therapies, and immunotherapy approaches offer hope for improving the long-term outlook for children affected by this devastating disease.